|
|
|
|
|
|
|
|
|
|
|
|
|
20.08.25 - 17:21
|
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension (GlobeNewswire EN)
|
|
|
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications....
|
|
|
|
|
15.08.25 - 03:30
|
Michael Burry Acquired Call Options on BABA-W/ JD-SW Last Qtr (AAStocks)
|
|
|
Michael Burry, a US hedge fund manager also known as the "Big Short" investor, acquired call options on BABA-W (09988.HK), JD-SW (09618.HK), ASML, Estee Lauder (EL.US), Lululemon Athletica (LULU.US), Meta (META.US), Regeneron Pharmaceuticals (REGN.US), UnitedHealth (UNH.US), and VF Corp (VFC.US) through his Scion Asset......
|
|
|
14.08.25 - 23:42
|
XFRA: DIVIDEND/INTEREST INFORMATION - 18.08.2025 - US75886F1075 (XETRA)
|
|
|
Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 15.08.2025 und ex Dividende/Zinsen am 18.08.2025
The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 15.08.2025 and its ex-dividend/interest day on 18.08.2025...
|
|
|
|
|
|
|
|
|
07.08.25 - 13:21
|
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline (Business Wire)
|
|
|
Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients
First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual MeetingBOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors.
The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironm...
|
|
|
|
|
|
|
04.08.25 - 09:45
|
Regeneron Pharmaceuticals: Langfristig gut aufgestellt (Sharedeals)
|
|
|
Trotz einiger Herausforderungen zeigt Regeneron Pharmaceuticals im zweiten Quartal 2025 eine beeindruckende Entwicklung. Während der Rückgang der Eylea-Umsätze weiterhin belastet, überzeugen andere Produkte durch starkes Wachstum und vielversprechende Pipeline-Fortschritte. Starke Quartalszahlen trotz Eylea-Schwäche Regeneron konnte mit seinen Quartalszahlen sowohl beim Gewinn je Aktie als auch beim Umsatz die Erwartungen übertreffen. Auch wenn das Augenmedikament Eylea […]
The post Regeneron Pharmaceuticals: Langfristig gut aufgestellt first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
